Baird lowered the firm’s price target on Owens & Minor to $24 from $28 and keeps a Neutral rating on the shares. The firm suspects the pullback is overdone and would be unsurprised by near-term recovery but the stock might need time to digest the latest update and greater buy-in from Street on merits of investing in med-surg distribution and direct-to-patient businesses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMI: